Vericel Corporation
Developer and manufacturer of autologous cell therapies and specialty biologics for cartilage repair and severe burn care. Maintains clinical development programs, GMP manufacturing and CMC capabilities for tissue-engineered and cell-based products; commercial supply and market-access operations; and regulatory, safety and quality systems to support licensed products and clinical studies.
Industries
Nr. of Employees
large (251-1000)
Vericel Corporation
Patents
Mixed cell populations for tissue repair and separation technique for cell processing
US-9415071-B2
View Details
Mixed cell populations for tissue repair and separation technique for cell processing
US-9415071-B2
View DetailsProducts
Autologous cultured chondrocyte implant on collagen membrane
A tissue-engineered autologous cell–scaffold implant produced by expanding a patient’s chondrocytes and seeding them onto a collagen membrane for repair of symptomatic full-thickness cartilage defects of the knee.
Cultured epidermal autografts for full-thickness burn coverage
Autologous cultured epidermal grafts grown from small skin biopsies to provide skin replacement for patients with extensive full-thickness burns when donor skin is limited.
Topical enzymatic eschar-debridement biologic
A topical proteolytic enzyme preparation applied to selectively remove eschar from deep partial- and full-thickness thermal burns to enable wound-bed assessment and subsequent treatment.
Autologous cultured chondrocyte implant on collagen membrane
A tissue-engineered autologous cell–scaffold implant produced by expanding a patient’s chondrocytes and seeding them onto a collagen membrane for repair of symptomatic full-thickness cartilage defects of the knee.
Cultured epidermal autografts for full-thickness burn coverage
Autologous cultured epidermal grafts grown from small skin biopsies to provide skin replacement for patients with extensive full-thickness burns when donor skin is limited.
Topical enzymatic eschar-debridement biologic
A topical proteolytic enzyme preparation applied to selectively remove eschar from deep partial- and full-thickness thermal burns to enable wound-bed assessment and subsequent treatment.
Services
Evaluation and funding of investigator-sponsored clinical trials, educational grants and charitable donations via a formal application and review process; provides budget templates and application guidance.
Commercial production, lot release testing and distribution of autologous cell therapy and specialty biologic products to hospitals and surgical centers, including logistics for clinical and commercial deliveries.
Policy-driven process and medical affairs point-of-contact for evaluating expanded access requests to investigational therapies for serious conditions.
Provision of intake channels (phone, email, downloadable form) and triage workflows for adverse events, medical device reports and product complaints, with internal reporting timelines and product disposition guidance.
Evaluation and funding of investigator-sponsored clinical trials, educational grants and charitable donations via a formal application and review process; provides budget templates and application guidance.
Commercial production, lot release testing and distribution of autologous cell therapy and specialty biologic products to hospitals and surgical centers, including logistics for clinical and commercial deliveries.
Policy-driven process and medical affairs point-of-contact for evaluating expanded access requests to investigational therapies for serious conditions.
Provision of intake channels (phone, email, downloadable form) and triage workflows for adverse events, medical device reports and product complaints, with internal reporting timelines and product disposition guidance.
Expertise Areas
- Cell therapy manufacturing and CMC
- Clinical trial management for orthopedics and burn care
- Regulatory strategy for biologics and combination products
- Quality systems, lot release and GMP compliance
Key Technologies
- Autologous cell expansion
- Cell–scaffold tissue-engineered manufacturing
- Animal-derived collagen membrane scaffolds
- Cultured epidermal autograft production
News & Updates
Public reporting of regulatory approval expanding arthroscopic delivery of a tissue-engineered autologous chondrocyte implant for certain knee defects.
Regulatory expansion to include pediatric patients for an enzymatic eschar removal biologic for treatment of deep partial- and full-thickness thermal burns.
Launch of an enzymatic eschar removal biologic in the U.S.; subsequent pediatric label expansion.
Public reporting of regulatory approval expanding arthroscopic delivery of a tissue-engineered autologous chondrocyte implant for certain knee defects.
Regulatory expansion to include pediatric patients for an enzymatic eschar removal biologic for treatment of deep partial- and full-thickness thermal burns.
Launch of an enzymatic eschar removal biologic in the U.S.; subsequent pediatric label expansion.